Sanifit Therapeutics, a Spain-based developer of treatments for vascular calcification disorders spun out of University of the Balearic Islands, has been bought by pharmaceutical group Vifor Pharma for €205m ($231m) upfront that could be expanded by up to €170m in clinical, regulatory and market access milestone payments. Sanifit had raised $149m as of a $62.8m…

The rest of this content is only accessible to Global Corporate Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.